Elizabeth Mobley, MD
Urology · Austin, TXNPI 1881847960
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Teleflex LLC accounts for 72.1% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2023 at $66,503 and has fallen 51.1% since, to $32,538 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 732 payments — averaging $347.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$183K
- Neotract Inc.$42K
- Johnson & Johnson$10K
- Medtronic$4K
- Ferring Pharmaceuticals Inc.$2K
- Janssen Scientific Affairs, LLC$2K
- plus $12K from 54 others
Across 2 payments — averaging $14,380 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neotract Inc.$29K
What the payments were for
- Consulting fees$108,14943%
- Speaking & faculty fees$118,88947%
- Travel & lodging$9,1854%
- Food & beverage$17,5727%
- Education$3690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$138,107
- UroLift System$70,983
- Barrigel$13,870
- RYBREVANT$6,498
- CARVYKTI$6,498
- INTERSTIM$3,276
- ADSTILADRIN$1,572
- Erleada$1,315
- eCoin Device Kit$773
- ILLUCCIX$609
- AquaBeam Robotic System$603
- Axonics$589
- AKEEGA$386
- XIAFLEX$256
- Balversa$150
- JELMYTO$149
- CVAC Aspiration System$148
- ALTIS$133
- Lupron Depot$119
- LithoVue$111
How this compares
$254,164 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 186 | $146,538 |
| GemtesaVibegron | 118 | $111,388 |
| OrgovyxRelugolix | 23 | $59,695 |
| Mirabegron ErMirabegron | 29 | $16,992 |
| Estradiol | 203 | $13,008 |
| Solifenacin Succinate | 53 | $2,791 |
| Potassium Citrate ErPotassium Citrate | 30 | $2,644 |
| Tamsulosin Hcl | 111 | $1,629 |
| Cephalexin | 68 | $457 |
| Oxybutynin Chloride ErOxybutynin Chloride | 37 | $422 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $213 |
| Ciprofloxacin Hcl | 29 | $191 |
| Oxybutynin Chloride | 19 | $116 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $56 |
| Prednisone | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $351 | $171,084141 claims |
| Astellas Pharma US IncMyrbetriq | $588 | $146,538186 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Austin
- Michael TrotterAustin$590K
- Varun SundaramAustin$400K
- Parviz KavoussiAustin$251K
- Peter RuffAustin$168K
- Bryan KansasAustin$120K
- Aaron LavianaAustin$78K
- Kyle KeyesAustin$58K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.